INTRODUCTION
============

Aldehyde dehydrogenase 2 (*ALDH2*) has a role in the metabolism of aldehydes \[[@B1]\], and its function in alcohol metabolism pathways has been well studied. However, many recent studies have reported that *ALDH2* may also be associated with chronic and age-related disorders.

A genome-wide association study (GWAS) performed in the Japanese population indicated that the chromosomal loci of 12q24, which is close to *BRAP* and *ALDH2*, is associated with coronary artery disease \[[@B2]\]. Similar results were reported in another GWAS in East Asians suggesting that 12q24.13, which is near to *ALDH2*, was strongly associated with blood pressure \[[@B3]\]. *ALDH2* polymorphism was linked to essential hypertension in Mongolians \[[@B4]\]. Hypertension is a component of metabolic syndrome, and interestingly, certain *ALDH2* genotypes have also been proposed as risk factors for metabolic syndrome with liver dysfunction \[[@B5]\].

Although benign prostate hyperplasia (BPH) and cardiovascular disease, which is associated with hypertension, arise due to separate pathological processes, both share similarities in age-related elevations in sympathetic tone that may contribute to the pathophysiology of disease \[[@B6]\]. Additionally, the International Prostatic Symptom Score (IPSS), which is usually used to assess BPH, was found to correlate with blood pressure \[[@B7]\]. In many cases, BPH coexists with diabetes \[[@B8]\] or metabolic syndrome \[[@B9]\]. Since such diseases are prevalent in aged men, there may be a genetic factor that affects the aging process and in turn, contributes to the underlying pathophysiology.

*ALDH2* is an isoform of aldehyde dehydrogenase present in mitochondria; a specific *ALDH2* polymorphism, known as *ALDH2^\*^2*, is present in North-East Asians \[[@B10]\]. Research suggests that *ALDH2* polymorphisms may exhibit deficient enzyme activity. *ALDH2* polymorphism is associated with late-onset Alzheimer disease in apolipoprotein E4 carriers, and mutant *ALDH2* is linked to cellular vulnerability to peroxidized lipids, which may lead to geriatric diseases \[[@B10]\].

Family history is a risk factor for BPH \[[@B11],[@B12]\], and disease features in BPH patients are linked to various genetic polymorphisms \[[@B13]-[@B16]\]. The aforementioned studies suggest that polymorphisms in *ALDH2* may increase the susceptibility to BPH, with no difference in the age of individuals and exposure to environmental factors and stressful conditions being observed in these studies \[[@B17]\]. However, there is a lack of studies examining whether *ALDH2* polymorphisms contribute to BPH. Therefore, in this study, we investigated the association of a single nucleotide polymorphism (SNP) in *ALDH2* with the onset and clinical features of BPH.

MATERIALS AND METHODS
=====================

Study subjects
--------------

BPH patients were recruited from Kyung Hee Medical Center between January 2002 and December 2008. [Table 1](#T1){ref-type="table"} displays the demographic and clinical features of the control and BPH groups. A total of 222 BPH patients and 214 control subjects were included in the study. The control group was composed of middle-aged to elderly males, who were free of a severe disease. The lower urinary tract symptoms (LUTS) of BPH patients were scaled using IPSS. Serum prostate-specific antigen (PSA) levels were tested in all BPH patients. Prostate sizes of the patients were estimated using transrectal ultrasound, and those patients who exhibited serum PSA levels above 4 ng/mL underwent prostate biopsies. Any patients with urinary tract infections, prostate cancer, a neurogenic bladder, uncontrolled diabetes mellitus, and/or cardiovascular diseases were not included in this study. In the analysis of clinical features, BPH patients were divided into groups based on the following features: IPSS (\<20 vs. ≥20), serum PSA level (\<1.5 ng/mL vs. ≥1.5 ng/mL), and prostate volume (\<30 mL vs. ≥30 mL) ([Table 1](#T1){ref-type="table"}). Ethical approval of this study was obtained from the Ethics Review Committee of Medical Research Institute, Kyung Hee University School of Medicine, Seoul, Korea.

SNP selection and genotyping
----------------------------

We selected one missense SNP, rs671 (Glu504Lys), of the *ALDH2* gene (<http://www.ncbi.nlm.nih.gov/SNP>) for analysis. Peripheral blood samples from each patient were stored in ethylenediaminetetraacetic acid in blood sampling tubes at -20℃. Genomic DNA was extracted using the QIAamp DNA mini kit (QIAGEN, Valencia, CA, USA). Polymerase chain reaction experiments were performed to amplify target sequences including rs671 (sense 5\'-CTCAGGAAGCTGAGGCAGGA-3\', antisense 5\'-GGCTGGGTCTTTACCCTCTC-3\', 652 base pairs). Direct sequencing and analysis were performed with an ABI PRISM 3730XL analyzer (PE Applied Biosystems, Foster City, CA, USA) and SeqManII software (DNASTAR, Madison, WI, USA).

Statistical analysis
--------------------

IBM SPSS ver. 20.0 (IBM Co., Armonk, NY, USA) was used to obtain odds ratios (ORs), 95% confidence intervals (CIs), and P-values adjusted for age as a covariable. Multiple logistic regression models (codominant1, codominant2, dominant, and recessive models) were applied in the analysis of genotypes. P\<0.05 was considered significant.

RESULTS
=======

The genotypic distribution of rs671 in the study subjects was in Hardy-Weinberg equilibrium (data not shown). The distribution of the tested SNP was not significantly different between control and BPH groups ([Table 2](#T2){ref-type="table"}). However, in the analysis of clinical features in BPH patients, the genotypes (codominant1: OR, 1.85; 95% CI, 1.04-3.30, P=0.037; dominant: OR, 1.92; 95% CI, 1.09-3.38, P=0.024) and allele distribution (OR, 1.65; 95% CI, 1.03-2.65; P=0.038) were associated with larger prostates in the BPH group ([Table 3](#T3){ref-type="table"}). IPSS ([Table 4](#T4){ref-type="table"}) and PSA ([Table 5](#T5){ref-type="table"}) were not significantly associated with rs671 in the tested population.

DISCUSSION
==========

*ALDH2* is located on 12q24.2 (<http://www.ncbi.nlm.nih.gov/gene/217>) and this locus has been linked to drinking behavior in the Chinese \[[@B18]\], alcohol dependence \[[@B19]\], squamous carcinoma \[[@B20]\], and obesity \[[@B21]\]. Moreover, a microdeletion in the locus was associated with insulin-dependent diabetes \[[@B22]\]. Such diseases, including obesity \[[@B23]\], are related to increased alcohol ingestion and ALDH2 activity in individuals. *ALDH2^\*^2* type, which is prevalent in North-East Asians, shows decreased enzyme activity \[[@B10]\]. Accordingly, rs11067228, which is a SNP on 12q24, was not associated with PSA levels in Caucasian men \[[@B24]\].

Aldehyde products in adipose tissue may contribute to obesity \[[@B23]\], and the detoxification of aldehydes may help protect against the oxidative stress of lipid oxidation \[[@B25]\]. ALDH2 belongs to the aldehyde dehydrogenase family, which functions to metabolize alcohols and other aldehyde derivatives produced in lipid metabolism \[[@B10]\]. This suggests that lipid peroxidation in prostate inflammation may be ameliorated by high ALDH2 activity, since reductions in aldehydes are beneficial in inflamed tissues \[[@B23],[@B26]\], and aldehyde production is significantly elevated in BPH \[[@B27]\].

Although many SNPs exist in the exon region of *ALDH2* (<http://www.ncbi.nlm.nih.gov/snp>), the majority are within the range of minor allele frequency (MAF) \<0.05, and there is an absence of genotype-phenotype correlations. One missense SNP, rs671, which was investigated in this study, is monotype (G allele) in the European population, MAF 0.156 (major allele G and minor allele A) in the Chinese population, and MAF 0.233 (also, major allele G and minor allele A) in the Japanese population. The MAF of rs671 in all subjects in this study was most similar to that of the Japanese population; however, the MAF in the control group was similar to the Chinese population. In line with previous studies, our results show that the missense *ALDH2* polymorphism, rs671 (Glu504Lys), may affect certain diseases in Asians.

The wild-type variant of rs671 is known as *ALDH2^\*^1* and the East Asian variant type, which is an inactive version of *ALDH2*, is called *ALDH2^\*^2* \[[@B28]\]. *ALDH2^\*^2* is associated with significantly lower activity in the metabolism of short chain aliphatic aldehydes, such as formaldehyde, propionaldehyde, n-butyraldehyde, capronaldehyde, and heptaldehyde \[[@B29]\]. Malondialdehyde is a short chain aliphatic aldehyde that has been considered as a marker for oxidative stress in many studies; it is also associated with prostate hypertrophy \[[@B27]\]. Previous research indicates a relationship between BPH and the biological function of *ALDH2* types.

In our study, rs671 was not associated with BPH development. However, prostate volume was associated with *ALDH2* type. Interestingly, a recent report suggested that chronic inflammation may lead to the progression of BPH, and such progression was characterized by prostate calcifications, volume, LUTS severity, and prostatitis-like symptoms \[[@B30]\]. This partly correlates with our observation that chronically elevated aldehyde levels may increase inflammatory responses in BPH, resulting in larger prostate volumes. The minor allele in this study was A, and this corresponds with the previously reported *ALDH2^\*^2* type, an inactive form that may lead to the decreased oxidation of aldehydes. The minor allele in this study was associated with elevated ORs (1.85 in codominant1, 1.92 in dominant, and 1.65 in alleles). Moreover, the dominant model correlated with a more progressive form of BPH (significant in age-adjusted males), which corresponds to previous findings that *ALDH2^\*^1/^\*^2* type exhibited reduced aldehyde metabolism \[[@B29]\].

In conclusion, we suggest that the missense *ALDH2* polymorphism, rs671, may contribute to BPH disease progression. There were limitations in our study: only Korean populations were included and hypertension was not analyzed due to inappropriate clinical data. Therefore, further study using a larger pool of BPH patients and more appropriate controls is required to confirm our results.
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The demographic and clinical features of the controls and BPH group (n=436)
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Values are presented as mean (±standard deviation).

BPH, benign prostate hyperplasia; IPSS, international prostate symptom score; PSA, prostate specific antigen.
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The genotypes and allele distributions of rs671 in the controls and BPH group
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SNP, single nucleotide polymorphism; BPH, benign prostate hyperplasia; OR, odds ratio; CI, confidence interval.
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The genotypes and allele distributions of rs671 in the groups divided based on prostate volume
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SNP, single nucleotide polymorphism; OR, odd ratio; CI, confidence interval.

###### 

The genotypes and allele distributions of rs671 in the groups divided based on IPSS
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Fisher exact P-values was calculated when the model include any cell with n\<6.

IPSS, international prostate symptom score; SNP, single nucleotide polymorphism; OR, odd ratio; CI, confidence interval.
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The genotypes and allele distributions of rs671 in the groups divided based on serum PSA level
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Fisher exact P-values was calculated when the model include any cell with n\<6.

PSA, prostate specific antigen; SNP, single nucleotide polymorphism; OR, odd ratio; CI, confidence interval.
